Gaboxadol Normalizes Behavioral Abnormalities in a Mouse Model of Fragile X Syndrome

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Fragile X syndrome (FXS) is a leading inherited cause of intellectual disability and autism.
• GABAergic system dysfunction, particularly involving extrasynaptic GABA_A receptors, is implicated in FXS pathophysiology.
• FXS is associated with hyperactivity, anxiety, aggression, and repetitive behaviors.

Purpose of the Study:

• To evaluate gaboxadol (OV101), a delta-subunit-containing extrasynaptic GABA_A receptor agonist, as a potential therapeutic for FXS.
• To assess gaboxadol's efficacy in normalizing behavioral deficits in the Fmr1 KO2 mouse model of FXS.

Main Methods:

• Utilized the Fmr1 KO2 mouse model, exhibiting FXS-like behaviors.
• Administered gaboxadol to Fmr1 KO2 mice.
• Assessed hyperactivity, anxiety, aggression, and repetitive behaviors using a battery of behavioral assays.

Main Results:

• Fmr1 KO2 mice displayed hyperactivity, abnormal anxiety, increased aggression, and repetitive behaviors compared to wild-type littermates.
• Gaboxadol treatment normalized all tested aberrant behaviors in Fmr1 KO2 mice to wild-type levels.
• Potentiation of extrasynaptic GABA receptors with gaboxadol was sufficient to ameliorate these behavioral deficits.

Conclusions:

• Gaboxadol demonstrates significant potential as a therapeutic agent for FXS.
• These findings support further clinical investigation of gaboxadol for FXS symptoms like hyperactivity, anxiety, aggression, and repetitive behaviors.